View Post Clinical Impact and Cost of Laboratory Monitoring Need Review Even in Resource-Rich Setting. Journal of Acquired Immune Deficiency Syndromes, 56(3): e97-e98. In by AHFMarch 1, 2011
View Post The 104 Day Report: A Successful Intervention of Improving Patient Retention. Clinical Infectious Diseases, 51(7): 868-869. In by AHFOctober 1, 2010
View Post DART and Laboratory Monitoring of HIV Treatment. The Lancet, 375 (9719): 979. In by AHFMarch 1, 2010
View Post Avoid a Different Standard of Care When Applying Results of Development of Antiretroviral Therapy in Africa (DART) Study. Journal of Acquired Immune Deficiency Syndromes, 53(1): 153-154. In by AHFJanuary 1, 2010
View Post Analysis of a Switch From Enfuvirtide to Raltegravir in Patients with Undetectable Viral Load: Efficacy and Quality of Life at 24 Weeks. Journal of the International Association of Physicians in AIDS Care, 8(2): 85-86. In by AHFMarch 1, 2009
View Post The Use of Darunavir/Ritonavir as Intensification in Low Viremic HIV-Infected Patients Treated with Boosted Protease Inhibitor-Containing Regimens. Journal of the International Association of Physicians in AIDS Care, 8(1): 21-22. In by AHFFebruary 1, 2009
View Post Meningitis Due to Hematogenous Dissemination of Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) in a Patient with AIDS. Journal of the International Association of Physicians in AIDS Care, 7(6): 289-291. In by AHFNovember 1, 2008
View Post No Residual Activity of Raltegravir After Development of 148 Complex Mutations In Vivo. Journal of the International Association of Physicians in AIDS Care, 7(6): 281-282. In by AHFNovember 1, 2008
